EISAI CO (ESALF) Financials
ESALF Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| 2023-12-31 | 9.3 billion | 3.3 billion |
| 2023-09-30 | 8.9 billion | 3.0 billion |
| 2023-06-30 | 9.0 billion | 3.0 billion |
| 2023-03-31 | 9.5 billion | 3.3 billion |
ESALF Free Cash Flow and Stock based compensation
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| 2023-12-31 | 7.6 million | ? |
| 2023-09-30 | 88.8 million | ? |
| 2023-06-30 | 28.2 million | ? |
| 2023-03-31 | 220.4 million | ? |
ESALF Net Income
| Date | Net Income |
|---|---|
| 2023-12-31 | 42.3 million |
| 2023-09-30 | 18.7 million |
| 2023-06-30 | 195.7 million |
| 2023-03-31 | 122.9 million |
ESALF Cash and Debt
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| 2023-12-31 | 2.0 billion | - | - |
| 2023-09-30 | 1.9 billion | - | - |
| 2023-06-30 | 1.9 billion | - | - |
| 2023-03-31 | 2.0 billion | - | - |
ESALF Shares Outstanding
ESALF Expenses
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| 2023-12-31 | 53.9 million | 295.7 million | 653.6 million | - |
| 2023-09-30 | 22.5 million | 278.7 million | 621.2 million | - |
| 2023-06-30 | 59.3 million | 284.7 million | 595.5 million | - |
| 2023-03-31 | 39.8 million | 388.5 million | 642.4 million | - |
ESALF Cost of Revenue
| Date | Revenue | Cost of Revenue |
|---|---|---|
| 2023-12-31 | 1.3 billion | 275.7 million |
| 2023-09-30 | 1.2 billion | 243.9 million |
| 2023-06-30 | 1.4 billion | 303.9 million |
| 2023-03-31 | 1.5 billion | 290.3 million |
ESALF
Price: $42.84
Dividend Yield: 2.39%
Forward Dividend Yield: 2.39%
Payout Ratio: 228.31%
Dividend Per Share: 2.35 USD
Earnings Per Share: 1.02 USD
P/E Ratio: 40.56
Exchange: PNK
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Market Capitalization: 12.8 billion
Average Dividend Frequency: 2
Years Paying Dividends: 21
DGR3: -7.68%
DGR5: 30.00%
DGR10: 30.00%